JPS58150596A - Deoxysarcophine - Google Patents

Deoxysarcophine

Info

Publication number
JPS58150596A
JPS58150596A JP57033432A JP3343282A JPS58150596A JP S58150596 A JPS58150596 A JP S58150596A JP 57033432 A JP57033432 A JP 57033432A JP 3343282 A JP3343282 A JP 3343282A JP S58150596 A JPS58150596 A JP S58150596A
Authority
JP
Japan
Prior art keywords
substance
deoxysarcophine
contraction
calcium
methanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP57033432A
Other languages
Japanese (ja)
Inventor
Junichi Kobayashi
淳一 小林
Yasushi Oizumi
康 大泉
Eiji Nakamura
英士 中村
Tadao Matsuzaki
尹雄 松崎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Kasei Corp
Original Assignee
Mitsubishi Kasei Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Kasei Corp filed Critical Mitsubishi Kasei Corp
Priority to JP57033432A priority Critical patent/JPS58150596A/en
Publication of JPS58150596A publication Critical patent/JPS58150596A/en
Pending legal-status Critical Current

Links

Abstract

NEW MATERIAL:16-Deoxysarcophine shown by the formula. USE:A calcium-antagonist, usable as a vasodilator or antispasmodic. PROCESS:For example, Sarcophyton sp., a kind of molluskan coral, is homogenized and extracted with a solvent such as methanol, etc., and fractionated by column chromatography, to give a compound shown by the formulaI.

Description

【発明の詳細な説明】 本尭―紘デオキシナルコフイyWlc関す為ものである
DETAILED DESCRIPTION OF THE INVENTION This invention relates to Motoya-Hirodeoxynarcophyy Wlc.

事−―看等は種々OSm動物体内に會すれる生1m5i
性物質を線素中Oところ、軟体ナンゴ〇−穏(saro
ophymonす→中に當すれる、あゐ種Oジテルペン
がカルシウム拮抗作用を示すことを発見した。
Matters--There are various types of care such as OSm.
When the sexual substance is in the filament, the soft body is saro.
It was discovered that a type O diterpene found in ophymon has a calcium antagonistic effect.

すなわち、哺乳動物の血管中腸管などの平滑筋中心筋等
O筋組織がカルシクムイオン(0−”)の作用に冬って
興奮、収縮すること社よく知られてお)、またhゐ種o
t*嵩有機化合物(有機塩基)が、C&1+イオンのこ
のような作用と特^6的に拮抗して、興奮、収縮を抑制
する作用を示すことも知られてs’ e 、このような
化合物はカルシクム詰抗ill (Oa−amtmgo
nlst)と呼けれている・カルシクム鶴抗薬は、上述
のように、例えば血管の興奮、収縮作用を抑制するので
、血管拡張、蘂又紘鎮瘤薬として使用される。
In other words, it is well known that O muscle tissue such as the smooth muscle central muscle of the blood vessels and midintestinal tract of mammals becomes excited and contracts in winter due to the action of calcium ions (0-''). o
It is also known that t* bulky organic compounds (organic bases) exhibit the effect of suppressing excitation and contraction by specifically antagonizing these effects of C&1+ ions, and such compounds Calcium packed antiill (Oa-amtmgo
As mentioned above, the anti-calcicum antidrug known as nlst) suppresses, for example, the excitation and constriction of blood vessels, and is therefore used as a drug for vasodilation and anti-inflammatory treatment.

本尭明看等は海置皇物を対象として、生S活性物質を一
索中Oとζろ、軟体ナンゴ〇一種(1&r@0ph7t
On sp、)中に、明瞭なカルシウム拮抗作用を示す
、次式(1)0立体構造を有する16デオ命ジチルコフ
イン(/4−4・o!ysaroophln* )Q存
在を確認し、これを単一することに成功し本斃明を遍成
しえ。すなわち、本尭tII#OII!旨紘、式(1) で示される14−デオキシナルコフィンに存するO 本発明を評mK説−するに、本*@t)ib−デオキシ
ナルコフィンは従来、軟体サンゴの成l; 分として、そO平面構造が推1m−11れていた線通r
tい未iawto物笈で番る・本物質性、軟体ナンゴ〇
一種(ilar・・ph7t・nsp、)をホ篭ジナイ
ズし 一1遥**s媒を層iて抽出し、カッ五!冒マドグラフ
ィーを用−て分画す為ことにより単離することがで[i 本尭@O物質紘、後記実施例に示すように、融点77〜
り1℃(未補正)を示し、円偏光二色性(Ol))スベ
タトル(メタノール)杜、JOOnm以上に有意なoo
tton効果を示さず、紫外線(EFT)1に収スペク
トル(メタノール)は、Joonym以上に極大吸収が
なく、また赤外線(XR)a収スペクトル(Klr)は
Jtoo。
This research focuses on Umiokikomonomono, and contains raw S active substances in O and ζro, and a type of soft Nango (1&r@0ph7t).
On sp,), we confirmed the presence of 16-deo-ditylcophin (/4-4・o!ysaroophhln*)Q, which has the following formula (1) 0 steric structure and exhibits a clear calcium antagonistic effect. Succeed in doing so, and accomplish the final death. In other words, Motoya tII#OII! According to the mK theory of the present invention, ib-deoxynarcofin is present in 14-deoxynarcofin represented by the formula (1). A line r where the planar structure was 1m-11
The real materiality, the soft-bodied Nango〇 type (ilar...ph7t, nsp,) is hodginized, and the 11 far**s medium is layered and extracted. It can be isolated by fractionation using chromatography [I Motoya @ O Materials, as shown in the examples below, the melting point is 77 ~
1℃ (uncorrected), circular dichroism (Ol)) Svetator (methanol)
It does not show the tton effect, its ultraviolet (EFT) absorption spectrum (methanol) has no maximum absorption than Joonym, and its infrared (XR) a absorption spectrum (Klr) is Jtoo.

/410./*参0、/JIO1140およびIダ0鋼
−1に徴収を示し、また、プロン)IMK、カーボンM
MRIよび!ススベクトル等O欄定結果から/6−デオ
命シf k :2 フィンであることが確認され、X線
解析によ〉、その立体構造が決定された。本発明の14
−チオ。キシIF”、A/ファインは、後記参考偶に示
すように、優れたカルシクム拮抗作用を示し、血管拡張
系、鎮痛薬として使用される。
/410. /* Reference 0, /JIO1140 and Ida0 steel-1, and also Pron) IMK, Carbon M
MRI call! It was confirmed from the results of soot vector determination that it was a /6-deoxyf k :2 fin, and its three-dimensional structure was determined by X-ray analysis. 14 of the present invention
-Thio. As shown in the references below, XyIF'' and A/Fine exhibit excellent calcium antagonistic effects and are used as vasodilators and analgesics.

以下、本発明を実施例についてさらに詳IIAK説−す
る。
Hereinafter, the present invention will be described in more detail with reference to Examples.

実施例 沖縄本島沿岸のtンゴ礁域で採職した軟体をンゴの一種
(laroophyzon sp、) l j 01を
破砕してホ峰ジtイズし、900−のメタノールを用i
てJ回抽出錫lを行ない、抽出液を減圧下SOυ以下で
蒸発乾固した。乾固物−!、41を、水/ 00114
および酢酸エチル100IIJの混合溶媒を用いて情出
分配を3回繰返したのち、酢酸エチル層を*b出し、減
圧下亭θ℃以下で蒸発乾固した。乾固物7.61を、n
−ヘキサンと酢酸エチルの混合液(1!量比3:l)を
展開溶媒として、シリカ、ゲル(K・1−・1g・16
Q1メルク社製、70〜JJ0メツシz ) J 00
1を充填し九カラム(長さ200■、直径JO■)にか
け、流出液をJvastづつ分散して活性を検査し、流
出開始後1000〜/ 1601tの活性分−を減圧下
aOO以下で蒸発乾固した。乾固物J、jtlを少蓋O
n−へキtyK#l解し、室温で放置し、析出した結晶
コ、/Iを再びn−へ命ナンに尋解し、憲温で放置し、
生成した無色プリズム状の結晶0.t jFを得た。本
物質の融点は77〜デt”0(未補正)を示し、ODス
ペクトぷ(メJOOnpm以上に他人吸収がなく、を九
工ft[収スペクトル(KBr)はλ900、/、Aj
O,/参uO1/310.140およびt#0es−”
  Kll収を示した。
Example: A type of coral (laroophyzon sp.) lj 01 was crushed and crushed into soft shells taken from a coral reef area off the coast of the main island of Okinawa, and then crushed using 900 methanol.
The extract was evaporated to dryness under reduced pressure below SOυ. Dry matter-! ,41,Wed/00114
After repeating the partitioning three times using a mixed solvent of 100 IIJ of ethyl acetate and 100 IIJ of ethyl acetate, the ethyl acetate layer was taken out and evaporated to dryness under reduced pressure below θ°C. Dry solids 7.61, n
- Silica, gel (K・1−・1g・16
Q1Merck, 70~JJ0 Metsushiz) J 00
1 was packed and applied to 9 columns (length 200 mm, diameter JO mm), the effluent was dispersed in Jvast portions and the activity was examined, and after the start of the flow, 1000 ~ / 1601 t of active content was evaporated to dryness under reduced pressure below aOO. Hardened. Dry solids J, jtl in a small lid O
Dissolve the precipitated crystals, /I, again in the n-column, and leave at room temperature.
Colorless prismatic crystals produced 0. t jF was obtained. The melting point of this substance is 77~det"0 (uncorrected), and the OD spectrum (KBr) is λ900, /, Aj
O,/reference uO1/310.140 and t#0es-”
Kll yield was shown.

本物質のマススペクトル紘30コ(M”) (計算値日 ’1@’IQO! : J OJ ) 、比旋光度[α
]っけ+/j70(0=/、0.メタノール)であった
。またlHNMR(ODOAm 270 MHg)は、
δt、oo(iH,rm )1、コ?(JH,8)、八
40(JH%S)、八4 j (J if。
The mass spectrum of this substance is 30K (M”) (calculated value date '1@'IQO!: JOJ), specific optical rotation [α
] +/j70 (0=/, 0.methanol). In addition, lHNMR (ODOAm 270 MHg) is
δt,oo(iH,rm)1,ko? (JH, 8), 840 (JH%S), 84 j (J if.

a)、八A 〜/、7 (コi!、m)、八13(21
1,a)、i、t  −λ、0(IH,m)、 、2.
/J(IH,In)、J、J参(IH,m)、J、Jt
(JH,m)、2.sll (IH,m)、−0り一(
/H% 1% J−ダ、jHg)、 ダ、j(コH% 
be)、s、i t (IH,!II)、 j、J、7
  (IH,dL% 10hm )、s、z+<iH,
鳳)0であった。また”OMMB (ODOLhJj、
J  Mlig)は、 170.a(q)、/l、z(
q)、/3.4((1)%  /7.o (q)、aJ
、s ($)、as、J(c)、コ!、/(1χ34、
り(す、 Jり、4 (t)、Jt、t(t、)、It
、t(c)、4八デ(L)、?L4!(す、tJ、t 
((1)、/J、7.4 (1)、/J4.J(A)、
lコア、l(畠)、 /、yJ、a(s)、/、74.
7 (す、/J?、、J(りであった。さらにX@解析
により本物質、すなわち、/4−デオキシサルコフィン
の立体構造を決定した0本憎質のステレオ投影画は#!
1図の通りである・ 参考例(薬理試験) 〔実験方法] く(イ) ウサギ嫡出血管に対する作用雄性ウサギ(J
、j−J時)をは(殺し、放血後脚部大動脈を摘出しら
縁状に切り、タレブスーリンゲル(Kr・M−Rlng
・r>m液を入れた容量−01Ltのマグヌス(Mag
nu・)管中に−画し良。その栄養液はJ7°に保ち、
91%O。
a), 8A ~/, 7 (koi!, m), 813 (21
1,a),i,t-λ,0(IH,m), ,2.
/J (IH, In), J, Jsan (IH, m), J, Jt
(JH, m), 2. sll (IH, m), -0 Riichi (
/H% 1% J-da,jHg), da,j(koH%
be), s, it (IH,!II), j, J, 7
(IH, dL% 10hm), s, z+<iH,
Otori) was 0. Also “OMMB (ODOLhJj,
J Mlig) is 170. a(q), /l,z(
q), /3.4((1)% /7.o (q), aJ
, s ($), as, J (c), Ko! , /(1χ34,
ri(su, Jri, 4 (t), Jt, t(t,), It
,t(c),48de(L),? L4! (S, tJ, t
((1), /J, 7.4 (1), /J4.J(A),
lcore,l(Hatake),/,yJ,a(s),/,74.
7 (S, /J?,,J(ri).Furthermore, the three-dimensional structure of this substance, that is, /4-deoxysarcophine, was determined by X@ analysis.The stereo projection image of 0 lines is #!
Figure 1 is as shown in Figure 1.Reference example (pharmacological test) [Experimental method]
After exsanguination, the leg aorta was removed and cut into margins, and Taleb Ringer (Kr. M-Rlng) was killed.
・Magnus (Mag) with a capacity of -01Lt containing r>m liquid
nu・) Good marking in the tube. The nutrient solution was kept at J7°,
91% O.

−j % 00.を通気した。この動脈切片に/1の静
止張力を付加し、IK物投与前/N間インキエベーV 
M / (inoubaszon) L九@その等優性
収縮の変化をトランスジューサーを介して記鎌針に記−
しえ。実施例で単一し九16−ゾオキシサルコフインを
栄養液中に各110111t′c#&加し、!OLおよ
びノルアドレナリン(noradrenalinりによ
る収縮反EhK対する影響を検討し良。
-j% 00. was ventilated. A resting tension of /1 was applied to this artery section, and an inkjet V
M / (inoubaszon) L9 @ Record the changes in the isodominant contraction on the sickle needle via the transducer.
Shie. In the example, each 110111t'c# & 916-zooxysarcofin was added to the nutrient solution, and! The effects of OL and noradrenaline on contractile anti-EhK should be investigated.

―) モルモット摘出消化管に対する作用雄性モルモッ
ト(コjO〜aooit)をぼ(殺し、放血後常法に従
って腸管および結腸縁を摘出した。栄養液はクレプス−
りンゲル溶液を用い、液温はJuoに保ち、9 j f
k Oa−5饅00.を通気した。この等中性状−をト
ランスジューサを介して記録した。これに実施例で単離
した16−デオキシサルコフィンを種々のtIkKで画
一し、カルノ(コール(caroachol)による収
縮反応に対する影Vt楓訂し九〇(ハ)マウスにおける
急性毒性試験 16−ジオキシサル・コフィンを生壊食塩液を用いて、
Isアラビアゴム騒S泳をしてマクスの体重−61幽p
 O,/創を投与するよう&C#4製しえ。生死の判定
はダI時間倣に行なった。なおマクスは+14i系薙性
て体1は209前後のを用いた。
-) Effect on removed digestive tract of guinea pigs Male guinea pigs (kojio~aooit) were killed, and after exsanguination, the intestines and colon margins were removed according to the standard method.The nutrient solution was
Using Ringer's solution, keeping the temperature at Juo, 9 j f
k Oa-5 rice cake 00. was ventilated. This isoneutral property was recorded via a transducer. In addition, the 16-deoxysarcophine isolated in the example was uniformly used with various tIkK, and the effect on the contractile response by caroachol was evaluated.・Coffin using raw saline solution,
Is Gum Arabic S Swimming and Max's Weight -61 Yup
O,/Make &C#4 to administer the wound. Judgment of life and death was made at the same time. For Max, I used +14i type Naginei, and for Body 1, I used around 209.

〔実験結果〕〔Experimental result〕

口) ウサギ嫡出血管 クサギ摘出胸す大動脈に於て16−デオキシサルコフィ
ン(以下本物質という)は10’〜5xto=bi  
tDIlkWIWc於てIlf依存性に参〇mMKOA
 Kよる収縮反応を抑制し、JX10″″1Mに於ては
はソ完全に抑制した。また10” Mのノルアドレナリ
ンによる収縮反応に対してはto−’No@WVC於て
もほとんど影響を与えなかった。これらのことから本−
質は外液のOa”の平滑筋細胞内への流入を増大させる
ζられる。まえ、本物質はKot%’(よる脱分極によ
って平滑筋sll!に流入するOaと競合的に拮抗する
ものと結論される0従って本物質はカルシクム拮抗作用
を有する薬物(Oa−拮抗済)として各樵血管拡591
!薬として利用される。
16-deoxysarcophine (hereinafter referred to as this substance) was found in the rabbit's thoracic aorta, which was removed from wedlock.
Ilf dependence in tDIlkWIWc
The contraction reaction caused by K was suppressed, and in JX10″″1M, it was completely suppressed. In addition, to-'No@WVC had almost no effect on the contractile response caused by 10"M noradrenaline. Based on these findings, this study
This substance increases the influx of external fluid Oa'' into smooth muscle cells. This substance competitively competes with Oa flowing into smooth muscle cells by depolarization caused by Kot%'(Kot%'). Therefore, it is concluded that this substance is a drug with calcium antagonistic action (Oa-antagonistic), which increases the blood vessel expansion of each woodcutter.
! Used as a medicine.

(ロ) モル毫ット摘出消化管 モルモット嫡出腸管に於て本物質祉/ 0 =〜1o4
hi omfK旋テII[依存性に10”MV)カルバ
コールによる収縮反応を抑制し、704Mに於てははソ
完全に抑制した。また、モルモット摘出結腸mにおいて
本物質は3X10”〜10” MのIII[に於て製置
依存性に10” MOカルバコールによる収縮反応(持
続性収縮成分)を抑制し、io糧麗に於いてはソ光全に
抑11+されえ。従って本物質は鎮漉薬として利用され
る・ (ハ)マウスに対する急性毒性 Xの腹腔的投与による”so ii/ 00〜/嗜以上
でめった。
(b) This substance in the excised gastrointestinal tract of the guinea pig and the intestinal tract of the guinea pig / 0 = ~ 1o4
hi omfK rotate II [dependently 10" MV) inhibited the contraction response induced by carbachol, and 704M completely inhibited the contraction response. In addition, in isolated guinea pig colons, this substance suppressed the contraction response of 3X10" to 10"M. In III, the contraction reaction (sustaining contraction component) caused by 10" MO carbachol was suppressed in a setting-dependent manner, and in IO, it was suppressed by Sokozen. Therefore, this substance is used as an antiperspirant. (c) Acute toxicity to mice caused by intraperitoneal administration of X.

【図面の簡単な説明】[Brief explanation of drawings]

纂/wJI/i、本命−のlb−デオキシサルコフィン
のステレオ投影−である。 出願人 三一化成工莱体式会社 代珈へ 弁壌士 長谷用   一 ほかl名
This is a stereo projection of the favorite lb-deoxysarcophine. Applicant: Sanichi Kasei Korai Taishiki Co., Ltd. Benyoshi: Yo Hase, and one other person

Claims (1)

【特許請求の範囲】[Claims] (1)式 で示1れる14−デオ命シナル4イy(1) Formula 14-deo life sinar 4iy indicated by 1
JP57033432A 1982-03-03 1982-03-03 Deoxysarcophine Pending JPS58150596A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP57033432A JPS58150596A (en) 1982-03-03 1982-03-03 Deoxysarcophine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57033432A JPS58150596A (en) 1982-03-03 1982-03-03 Deoxysarcophine

Publications (1)

Publication Number Publication Date
JPS58150596A true JPS58150596A (en) 1983-09-07

Family

ID=12386377

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57033432A Pending JPS58150596A (en) 1982-03-03 1982-03-03 Deoxysarcophine

Country Status (1)

Country Link
JP (1) JPS58150596A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105732656A (en) * 2016-03-31 2016-07-06 中国人民解放军第二军医大学 Tetraterpene compound in Sarcophyton and use of tetraterpene compound

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105732656A (en) * 2016-03-31 2016-07-06 中国人民解放军第二军医大学 Tetraterpene compound in Sarcophyton and use of tetraterpene compound

Similar Documents

Publication Publication Date Title
KR101515681B1 (en) Scf extract containing cardiac glycoside
US3093831A (en) Artificial gland
Likoff et al. Evaluation of “coronary vasodilators” by coronary arteriography
Henriksson et al. Uptake of inorganic mercury in the olfactory bulbs via olfactory pathways in rats
RU99104404A (en) PHARMACEUTICAL COMPOSITION OF MANY SUBSIDIARIES AND METHOD FOR PRODUCING IT
JPS58150596A (en) Deoxysarcophine
Karel Gastric absorption
DE59708666D1 (en) TETRAETHER LIPID AND LIPOSOMES THEREOF AND THEIR USE
RU95112577A (en) 1,4-disubstituted piperazines useful for asthma and respiratory ways inflammation treatment, method of their synthesis, medicinal preparations made of their base and method of their preparing
Hanlon et al. Experimental tuberculosis: I. Effects of anastomosis between systemic and pulmonary arteries on tuberculosis in monkeys
Rogers et al. Experimental production of supravalvular aortic stenosis in the dog
Buchanan et al. Uptake and retention of fixed carbon in adult mice
Bamber Metaphor and illness classification in traditional Thai medicine
Lee et al. Improvement in RBC flux, acidosis and oxygenation in tumour microregions by Fluosol-DA 20%
Dorland The American Illustrated Medical Dictionary: A New and Complete Dictionary of the Terms Used in Medicine, Surgery, Dentistry, Pharmacy, Chemistry, and the Kindred Branches, with Their Pronunciation, Derivation and Definition
JPS58135806A (en) Multi-layered coating pharmaceutical preparation
Burgener et al. Contraction of the canine gallbladder in different degrees of common bile duct obstruction
Qwarnström et al. Normal radiographic anatomy of the rat submandibular gland
SU1326246A1 (en) Method of investigating gall bladder
ATE66815T1 (en) MEDICATION CONTAINING AN ORGAN EXTRACT PRODUCED FROM PEYER&#39;S PLAQUES FOR THE TREATMENT OF DIABETES MELLITUS AND PANCREATITIS.
Neubauer et al. A Guide to the Qualitative and Quantitative Analysis of the Urine: Designed Especially for the Use of Medical Men
WO2022099565A1 (en) Red-light-mediated nucleic acid anchoring-type fluorescent probe, and preparation method therefor and use thereof
CECIL et al. Observations on the excretion of dyes
Mould Early Days of X-rays and Radium: Diagnosis, Therapy and Experiment
JPS58162541A (en) Nootkatol